American Parkinson Disease Association (APDA) Center for Advanced Research
The University of Pittsburgh is home to an Advanced Center for Parkinson’s Research supported by the American Parkinson Disease Association. The Center is directed by J. Timothy Greenamyre with a comprehensive team of experts.
APDA Centers for Advanced Research must meet the highest academic standards and be distinguished leaders in the field of PD research. There are eight such centers across the country
The funding of this Center supports a large research program, which includes: Neurologists, Neuroscientists, Postdoctoral Fellows, Graduate and Undergraduate Students and Movement Disorders Fellows, as well as a Physician Assistant, Nurse and Clinical Research Coordinators. Projects range from basic laboratory bench studies to translational testing of new therapeutic strategies to clinical trials of new treatments for people with PD. The University of Pittsburgh Center has experience with both experimental and clinical gene therapy studies.
The American Parkinson Disease Association (APDA) is the largest grassroots network dedicated to fighting Parkinson’s disease (PD) and works tirelessly to assist the more than 1 million Americans with PD live life to the fullest in the face of this chronic, neurological disorder. Founded in 1961, APDA has raised and invested more than $170 million to provide outstanding patient services and educational programs, elevate public awareness about the disease, and support research designed to unlock the mysteries of PD and ultimately put an end to this disease. To join us in the fight against Parkinson’s disease and to learn more about the support APDA provides nationally through our network of Chapters and Information & Referral (I&R) Centers, as well as our national Research Program and Centers for Advanced Research, please visit us at www.apdaparkinson.org
Parkinson’s disease affects more than 1 million people in the United States annually, with at least 60,000 new cases diagnosed each year. The chronic and progressive neurological condition is the second most common neurodegenerative aging disorder, after Alzheimer’s disease.
For more information contact:
Medical Director: J. Timothy Greenamyre, MD, PhD